Physician profile
Travis Doyle Weaver
NPI 1063808772
$3,754.61
in general payments reported to CMS, 2019-2025
28 companies · $2,197 in 2025
The $2,197 reported for 2025 was more than what 78% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $767 · 2020: $13.64 · 2024: $777 · 2025: $2,197.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,735 · Consulting Fee: $175 · Education: $63.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,735.37 |
| Consulting Fee | $175.00 |
| Education | $63.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $750.00 | 2019 | |
| Insulet Corporation | $495.39 | 2024-2025 | Omnipod |
| Tandem Diabetes Care, INC. | $388.98 | 2024-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $290.45 | 2024-2025 | Prolia, Evenity, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $235.13 | 2024-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $215.44 | 2024-2025 | |
| Lilly USA, LLC | $193.77 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $190.44 | 2025 | Korlym |
| Amneal Pharmaceuticals LLC | $176.40 | 2024-2025 | Unithroid |
| Novo Nordisk INC | $125.09 | 2024-2025 | Rybelsus, Ozempic |
| Abbott Laboratories | $73.19 | 2025 | Freestyle Libre 3 |
| Sequel Med Tech, LLC | $72.76 | 2025 | Twiist |
| Radius Health, INC. | $64.37 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $63.15 | 2024-2025 | |
| Dexcom, INC. | $57.84 | 2024-2025 | Dexcom G6 Transmitter |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $47.32 | 2025 | Inpen Smart Insulin Delivery System |
| Xeris Pharmaceuticals, INC. | $43.85 | 2025 | Recorlev, Gvoke Hypopen |
| Beta Bionics, INC. | $36.04 | 2024 | Ilet Bionic Pancreas |
| Neurocrine Biosciences, INC. | $35.40 | 2025 | |
| Madrigal Pharmaceuticals | $34.80 | 2025 | Rezdiffra |
| Cequr Corporation | $27.51 | 2025 | Cequr Simplicity |
| Ionis Pharmaceuticals, INC. | $24.01 | 2025 | Tryngolza |
| Recordati_rare_diseases_inc. | $23.46 | 2025 | Isturisa |
| Kyowa Kirin, INC. | $22.81 | 2025 | |
| Ascendis Pharma Endocrinology INC | $22.23 | 2025 | Yorvipath |
| Endo Pharmaceuticals INC. | $16.75 | 2019 | |
| Soleno Therapeutics, INC. | $14.39 | 2025 | Vykat Xr |
| Companion Medical, INC. | $13.64 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.